AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

AbCellera Biologics Inc.NASDAQ: ABCL

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit turns negative

Q3 FY2026 gross profit was -$53.32M, compared with $8.96M a year earlier. Trailing-twelve-month gross profit was -$12.67M. Over 3 fiscal years it compounded at -52.0% a year.

Context

  • Gross profit amounted to 61.6% of revenue in FY2025, down 38.4 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$53.32M or moves back toward the trailing-twelve-month quarterly average of -$3.17M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$53.32M-1416.4% QoQ
Last fiscal yearDec 2025
$46.31M+60.6% YoY
LTMSep 2026
-$12.67M-135.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-695.4%——
1 year+60.6%——
3-year CAGR-52.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
46.31M USD
Year-over-year change
+60.6%
4-year CAGR
-38.8%

Gross Profit vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 gross profit of -$12.67M is the 3rd highest of the 4 companies compared; the peer median is $31.89M.
  • Its year-over-year change of -135.9% is the lowest of 4, against a peer median of +48.7%.
  • Gross profit amounts to 18.7% of revenue for ABCL, versus a peer median of 100.0%.
ABCL Competitors Peer median
Gross Profit for ABCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$105.94M -44.8%-20.3%75.0%
GENBGenerate Biomedicines, Inc.FY2025$31.89M +55.9%—100.0%
ABCLAbCellera Biologics Inc.LTM Sep 2026-$12.67M -135.9%-52.0%18.7%
ABSIAbsci CorporationLTM Mar 2026-$24.18M +48.7%—1316.9%
Peer median (excluding ABCL) $31.89M+48.7%-20.3%100.0%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue375.2M485.42M38.03M28.83M75.13M
Cost of Revenue45.52M66.44M0028.82M
Gross Profit329.69M418.99M38.03M28.83M46.31M
Gross Margin87.9%86.3%100.0%100.0%61.6%
Research & Development62.06M107.88M175.66M167.26M186.83M
Selling, General & Admin48.76M66.76M75.18M85.49M76.58M
Operating Expenses125.27M202.48M275.23M343.6M263.41M
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
EBITDA239.15M260.17M(192.16M)(204.15M)(148.77M)
EBITDA Margin63.7%53.6%-505.3%-708.0%-198.0%
Operating Income204.41M216.51M(237.21M)(314.77M)(217.1M)
Operating Margin54.5%44.6%-623.8%-1091.7%-289.0%
Interest Income3.33M16.08M42.25M38.47M28.33M
Interest Expense5.23M4.05M000
Other Income / Expenses14.74M22.59M63.18M114.37M39.51M
Income Before Tax219.15M239.1M(174.03M)(200.4M)(177.6M)
Pre-Tax Margin58.4%49.3%-457.7%-695.0%-236.4%
Income Tax Expense65.69M80.58M(27.63M)(37.54M)(31.18M)
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Net Margin40.9%32.7%-385.0%-564.8%-194.9%
EPS (Basic)0.560.56(0.51)(0.55)(0.49)
EPS (Diluted)0.480.50(0.51)(0.55)(0.49)
Weighted Avg Shares275.76M285.06M289.17M294.33M298.71M
Weighted Avg Shares (Diluted)318.29M314.83M289.17M294.33M298.71M

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.